drugset / Trial / NCT00306150

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

NCT00306150

Phase 3 Terminated 57 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess if aprotinin (BAYA0128), given intravenously during your surgery, is safe and can help reduce the need for a blood transfusion during bladder surgery.

Timeline

Start
2005-12
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprotinin Unknown 500000 unknown Intravenous

Indications

No indication recorded.